<DOC>
	<DOCNO>NCT00492960</DOCNO>
	<brief_summary>This study look 3 dos AT1001 efficacy safety treatment celiac disease . The primary efficacy outcome evaluate efficacy multiple dose level AT-1001 prevent intestinal permeability change induce 6- week gluten challenge .</brief_summary>
	<brief_title>Phase IIb Study Study Efficacy AT1001 Treat Celiac Disease</brief_title>
	<detailed_description>This outpatient , randomize , double blind multicenter study . Subjects remain gluten-free diet throughout duration trial . Study drug drug placebo capsule administer TID 15 minute meal ( breakfast , lunch , dinner ) . Gluten gluten placebo capsule take TID meal .</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Eligible subject must meet follow criterion enrol study : 1 . Age 18 72 year , inclusive . 2 . Diagnosed celiac disease 6 month . 3 . AntiTissue Transglutaminase ( antitTG ) less 10 EU . 4 . On glutenfree diet least 6 month . 5 . BMI 18.5 38 , inclusive . Exclusion Criteria Subjects meet one follow criterion eligible study : 1 . Current smoker . 2 . Has chronic active GI disease celiac disease ( e.g . Crohn 's , Colitis ) . 3 . Has diabetes ( Type 1 Type 2 ) . 4 . Unable abstain alcohol consumption 48 hour prior intestinal permeability collection throughout study . 5 . Unable refrain consume nonsteroidal antiinflammatory agent , include aspirin ( `` NSAIDs '' ) 48 hour prior intestinal permeability collection throughout study . 6 . Participated clinical drug study within past 30 day previous exposure AT1001 . 7 . Presents history dermatitis herpetiformis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Celiac Disease</keyword>
</DOC>